Targeted Neuro Delivery Karamedica is building a nose-to-brain delivery platform using chitosan and microparticles for cerebral conditions, supported by NIH SBIR funding. Potential sales opportunities include partnerships or pilots with biotech firms and contract research organizations focused on CNS drug delivery, neurodegenerative disease research, or aging-related therapies.

NIH Backed Validation With NIH SBIR Phase II funding and ongoing government support, Karamedica possesses credible validation for its delivery technology. Sales potential exists in engaging with government-funded programs, public-private collaborations, and grant-aligned customers seeking compliant, funded CNS delivery solutions.

Emerging Therapeutic Focus The company expands therapeutic uses of biopolymer-based products, notably chitosan, for non-viral delivery. This opens cross-sell opportunities to biotech teams exploring alternative delivery vectors, formulation services, and early-stage product development collaborations across neurology, oncology, and infectious disease applications.

Early Market Position As a small, 2-10 employee biotech startup with 1M-10M in revenue, Karamedica may partner with larger CROs, contract manufacturers, and pharma players needing nimble, innovative CNS delivery capabilities, pilot programs, or co-development arrangements to accelerate time-to-market.

Strategic Partnerships Recent news highlights potential for collaboration with academic institutions and neurology-focused entities investigating cerebral amyloid angiopathy and Alzheimer's-related brain therapies. Business development can target collaborations that leverage Karamedica’s nanoparticle and nose-to-brain platform for joint R&D, licensing, or sponsored research agreements.